New research has dismissed the cardiac safety concerns associated with the Hydroxychloroquine (HCQ) treatment combined with Azithromycin, Vitamin C, Vitamin D, and Zinc. The study, conducted by ProgenaBiome researchers, indicates that this treatment does not have significant cardiac risks for critically ill COVID-19 patients.
The study monitored 83 patients using continuous EKG and statistical analysis over ten days. Results showed no significant differences in the QTc interval, a key measure of cardiac risk, between patients receiving the treatment and those on placebo. This finding is significant given that concerns over QTc interval prolongation have hindered HCQ's use in COVID-19 therapy.
The retraction of a previous influential study on this combination therapy has drawn controversy, with accusations of unethical suppression driven by the interests of the biopharmaceutical industry, which is seen as favoring profit over public health. Concerns have been raised about the promotion of expensive mRNA vaccines over cheaper, proven treatments like HCQ.
The study urges policymakers to prioritize evidence-based treatments and challenge the ongoing suppression of alternative COVID-19 therapies. Researchers advocate for a commitment to scientific truth and public health, arguing for the importance of making affordable treatments accessible to those in need.
The implications of the ProgenaBiome study are significant, suggesting that hydroxychloroquine could be a safe and effective outpatient treatment option for COVID-19. This challenges existing market forces and encourages a reevaluation of health policies regarding accessible care in the context of a global pandemic.
The authors emphasize their dedication to high-quality research and ensuring effective treatments are made available, stressing the need to protect scientific integrity against commercial interests. This research reflects the ongoing commitment to truth in the medical field and serves as a rallying point for evidence-based practices in healthcare.
The study concludes that the combination of Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, and Zinc stands as a credible treatment option without significant cardiac complications, adding to the dialogue surrounding effective COVID-19 responses and the ethical responsibilities of the health industry.
https://www.naturalnews.com/2024-12-20-new-research-debunks-cardiac-safety-smear-campaign.html
No comments:
Post a Comment